Film history is littered with unauthorized movie sequels. For example, John Howley's 1989 animated film "Happily Ever After" was conceived as an unofficial "Snow White" sequel until Disney forced it ...

Regal Cinemas will launch its second annual “Month of Masterpieces” showcase of classic films next month, as acclaimed filmmakers Chloe Zhao, Edgar Wright, Gina Prince-Bythewood and Rian Johnson will ...

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Braveheart Bio (NasdaqGM: BRVE) completed its IPO and listed on the Nasdaq Global ...

One takeaway from this year’s surge of biotech IPO activity is that investors want to see at least some clinical data before a company makes its stock market debut. Braveheart Bio has mid-stage trial ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company looks to be in late ...

Braveheart Bio has emerged on the Nasdaq with an upsized expected initial public offering—marking the public entrance of the twenty-second biotech this year. Cardiovascular-focused Braveheart Bio is ...

The IPO haul could rise by around $57.4 million if underwriters fully take up their option to acquire an additional 3.2 million shares. (iStock / Getty Images Plus) Braveheart Bio has overcome its own ...

Braveheart Bio (Nasdaq: BRVE), a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, ...

Braveheart Bio, Inc. (BRVE) has filed proposed terms for a $300 million IPO of its common stock, per an SEC S-1/A registration statement. The firm is a clinical-stage biopharma developing a treatment ...

Medieval historian and co-host of the 'Gone Medieval' podcast, Matt Lewis, deep dives into the historical accuracy of the highly controversial movie 'Braveheart'. You can now become a History Hit ...

Clinical-stage biopharma companies Braveheart Bio (BRVE) and Attovia Therapeutics (ATTO) have announced plans to raise $274.5M and $182.4M in net proceeds, respectively, from their initial public ...